Vernalis PLC' AUY922 Update
AUY922 is included for the first time in Novartis’ selected pharmaceutical pipeline projects chart.
More information can be found on Novartis’ website (www.novartis.com).
Enquiries:
Vernalis Contacts
Ian Garland, Chief Executive Officer +44 (0) 118 989 9360
David Mackney, Chief Financial Officer
Brunswick Group
Jon Coles +44 (0) 20 7404 5959
Justine McIlroy
Taylor Rafferty
Rob Newman +44 (0) 20 7614 2900
Faisal Kanth
About Vernalis
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are the subject of collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.